EP1305021A4 - Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition - Google Patents

Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Info

Publication number
EP1305021A4
EP1305021A4 EP01946709A EP01946709A EP1305021A4 EP 1305021 A4 EP1305021 A4 EP 1305021A4 EP 01946709 A EP01946709 A EP 01946709A EP 01946709 A EP01946709 A EP 01946709A EP 1305021 A4 EP1305021 A4 EP 1305021A4
Authority
EP
European Patent Office
Prior art keywords
composition
dosage forms
therapeutic agents
controlled release
forms including
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01946709A
Other languages
German (de)
French (fr)
Other versions
EP1305021A1 (en
Inventor
Moshe Fleshner-Barak
E Itzhak Lerner
Vered Rosenberger
Mazal Dahan
Yisrael Imakov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of EP1305021A1 publication Critical patent/EP1305021A1/en
Publication of EP1305021A4 publication Critical patent/EP1305021A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Manufacturing & Machinery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
EP01946709A 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition Withdrawn EP1305021A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US21383200P 2000-06-23 2000-06-23
US213832P 2000-06-23
US21711000P 2000-07-10 2000-07-10
US217110P 2000-07-10
US22321200P 2000-08-04 2000-08-04
US223212P 2000-08-04
PCT/US2001/020134 WO2002000213A1 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Publications (2)

Publication Number Publication Date
EP1305021A1 EP1305021A1 (en) 2003-05-02
EP1305021A4 true EP1305021A4 (en) 2009-09-23

Family

ID=27395915

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01946709A Withdrawn EP1305021A4 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Country Status (11)

Country Link
EP (1) EP1305021A4 (en)
JP (1) JP2004501190A (en)
KR (1) KR20030013460A (en)
AU (2) AU6872201A (en)
CA (1) CA2412490A1 (en)
CZ (1) CZ2003199A3 (en)
EA (1) EA200300046A1 (en)
HU (1) HUP0301465A3 (en)
IL (1) IL153497A0 (en)
MX (1) MXPA02012793A (en)
WO (1) WO2002000213A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
JP2005501097A (en) * 2001-08-16 2005-01-13 ザ ステイト オブ オレゴン アクティング バイ アンド スルー ザ ステイト ボード オブ ハイアー エデュケイション、 オン ビハーフ オブ オレゴン ステイト ユニバーシティー Inflatable gastric retention device
BE1015608A6 (en) 2003-07-15 2005-06-07 Messadek Jallal TREATMENT arteritis.
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
DE602004003577T2 (en) * 2003-04-17 2007-09-20 Jallal Messadek Floating oral formulations with controlled release of betaine
KR20080109101A (en) * 2003-10-20 2008-12-16 테바 파마슈티컬 인더스트리즈 리미티드 Compositions and formulations for the sustained effect of levodopa
JP2005132803A (en) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd Gastric retention solids
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
FR2874325B1 (en) * 2004-08-19 2006-10-20 Sanofi Synthelabo PHARMACEUTICAL COMPOSITION IN THE FORM OF A GASTRIC RESISTANCE COMPRESSOR CONTAINING ALFUZOSIN
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
BRPI0610249A2 (en) 2005-04-27 2010-06-08 Jallal Messadek pharmaceutical combination or combination, pharmaceutical composition, co-crystallization process and the use of insulin or insulin analogue
NL2000281C2 (en) 2005-11-02 2007-08-07 Pfizer Prod Inc Solid pharmaceutical compositions containing pregabalin.
RU2484815C2 (en) * 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Continuous 24-hour introduction of levodopa/carbidopa into intestine
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
PE20080669A1 (en) * 2006-09-08 2008-07-18 Drugtech Corp SUSTAINED RELEASE COMPOSITION INCLUDING LEVODOPA
WO2008039186A2 (en) * 2006-09-26 2008-04-03 Plensat, Llc Method and system for treatment of eating disorders
JPWO2008087882A1 (en) 2007-01-15 2010-05-06 キッセイ薬品工業株式会社 Stomach retention type levodopa sustained release formulation
KR20080076382A (en) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 Controlled-Release Formulation of Cilostazol and Method for Preparing the Same
DE102007026037A1 (en) * 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentive system with alginate body
EP2192892A2 (en) * 2007-07-27 2010-06-09 Depomed, Inc. Pulsatile gastric retentive dosage forms
MX337213B (en) 2008-06-30 2016-02-17 Tocagen Inc Formulations of 5-fluorocytosine and uses thereof.
JP2012500221A (en) * 2008-08-15 2012-01-05 ディポメド，インコーポレイティド Gastric retentive pharmaceutical composition for treatment and prevention of CNS disorders
CA2742680C (en) * 2008-11-07 2013-12-31 Samyang Corporation Pharmaceutical compositions for release control of methylphenidate
WO2012093974A1 (en) * 2011-01-06 2012-07-12 Mahmut Bilgic Improved bisphosphonate formulations
CN103385871B (en) * 2012-05-07 2017-06-23 新疆医科大学 Benserazide micro-capsule floating tablet
DK2858604T3 (en) 2012-06-07 2024-05-21 Epitomee Medical Ltd EXPANDED DEVICE
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
JP6204141B2 (en) * 2013-04-22 2017-09-27 テイカ製薬株式会社 Oral rapidly disintegrating composition for solid preparation
US10994013B2 (en) 2013-04-24 2021-05-04 Temple University—Of the Commonwealth System of Higher Education Solid dosage form containing arabinogalactan
AU2014332024B2 (en) 2013-10-07 2019-09-26 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
WO2015083171A1 (en) * 2013-12-05 2015-06-11 Tulip Medical Ltd. Retentive devices and systems for in-situ release of pharmaceutical active agents
PT3261625T (en) * 2015-02-27 2024-11-18 Cingulate Therapeutics LLC Tripulse release stimulant formulations
JP6823539B2 (en) * 2017-05-26 2021-02-03 株式会社ファンケル Gastric retention tablets
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
EP3648747B1 (en) 2017-06-16 2022-09-07 Amneal Complex Products Research LLC Gastroretentive dosage forms for sustained drug delivery
ES2861153T3 (en) 2018-06-18 2021-10-05 Extended Release Compositions Comprising Pyridostigmine
JP7034343B2 (en) 2018-06-27 2022-03-11 アムニール コンプレックス プロダクツ リサーチ エルエルシー Self-regulating permeable gastric retention drug delivery system
JP7044649B2 (en) * 2018-06-28 2022-03-30 株式会社ファンケル Intragastric floating tablets
EP3968980A1 (en) 2019-05-14 2022-03-23 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2020264092A1 (en) * 2019-06-26 2020-12-30 Celista Pharmaceuticals Llc Atomoxetine hydrochloride extended release compositions and methods of use
JP7624750B2 (en) 2020-03-02 2025-01-31 クラフト ヘルス プライベート リミテッド Oral dosage forms for sustained drug release
EP4267113A4 (en) 2020-12-22 2025-02-12 Amneal Pharmaceuticals LLC Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11571402B2 (en) * 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
EP0795324A2 (en) * 1996-02-19 1997-09-17 Jagotec Ag A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
WO1999004764A1 (en) * 1997-07-23 1999-02-04 Perio Products Ltd. Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
EP0795324A2 (en) * 1996-02-19 1997-09-17 Jagotec Ag A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
WO1999004764A1 (en) * 1997-07-23 1999-02-04 Perio Products Ltd. Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0200213A1 *

Also Published As

Publication number Publication date
EP1305021A1 (en) 2003-05-02
JP2004501190A (en) 2004-01-15
CZ2003199A3 (en) 2003-12-17
KR20030013460A (en) 2003-02-14
AU6872201A (en) 2002-01-08
EA200300046A1 (en) 2003-10-30
AU2001268722B2 (en) 2005-08-11
HUP0301465A3 (en) 2006-07-28
IL153497A0 (en) 2003-07-06
HUP0301465A2 (en) 2004-05-28
CA2412490A1 (en) 2002-01-03
AU2001268722B8 (en) 2005-09-29
WO2002000213A1 (en) 2002-01-03
MXPA02012793A (en) 2004-07-30

Similar Documents

Publication Publication Date Title
AU6872201A (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
IL154521A0 (en) Contraception process and administration form for the same
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
MXPA03003895A (en) Controlled release hydrocodone formulations.
HUP0301242A3 (en) Controlled release drug dosage form
AU2001253479A1 (en) Targeted therapeutic agent release devices and methods of making and using the same
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL153708A0 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU2002360717A1 (en) Controlled release dosage form having improved drug release properties
GB0002386D0 (en) Therapeutic composition
FI20000780L (en) Oral dosage form for controlled release of the drug
MXPA03004303A (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain.
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HUP0204417A3 (en) Oral ciprofloxacin-composition of controlled release
IL137275A0 (en) Pharmaceutical composition for the treatment of anal fissures
EP1357898A4 (en) Improved controlled release oral dosage form
GB0030067D0 (en) Therapeutic agent
IL155819A0 (en) Methods of treatment comprising administration of substance p
PH12001001922B1 (en) Crystalline therapeutic agent.
IL135993A0 (en) Pharmaceutical composition for the treatment of fibrosis
AU6884801A (en) Therapeutic compounds and methods
EP1338275A4 (en) Pharmaceutical composition, the use thereof and method for producing said composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030121

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20090825

17Q First examination report despatched

Effective date: 20100816

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101228